問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



China Medical University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 2,076

    Total Beds

  • 884

    Total Doctors

  • ctcadm.cmuh@gmail.com
  • Clinical Trial Center
  • 04-22052121#1471~1485
  • 404Taichung CityTaichung NorthNo. 2, Yude Rd., North Dist., Taichung City 404332, Taiwan (R.O.C.)

Recruiting Trial

681Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1712Cases

2011-06-01 - 2014-12-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2012-06-01 - 2018-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2012-09-01 - 2016-12-31

Phase III

A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etoposide (CE) Alone in Chemotherapy Naïve Patients with Extensive-Stage Small Cell Lung Cancer. The MATISSE Study

  • Condition/Disease

    Small cell lung cancer

  • Test Drug

    Palifosfamide-tris

Participate Sites
7Sites

Terminated7Sites

2013-12-01 - 2018-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2013-02-01 - 2021-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-11-01 - 2021-12-31

Phase III

Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection

  • Condition/Disease

    C. difficile Infection

  • Test Drug

    C. difficile Toxoid Vaccine

Participate Sites
7Sites

Terminated7Sites

2011-05-01 - 2014-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2017-04-05 - 2018-09-27

Phase II/III

A TWO-PART PHASE 2/ 3 MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY OF VARLITINIB PLUS MFOLFOX6 VERSUS PLACEBO PLUS MFOLFOX6 IN SUBJECTS WITH HER1/ HER2 CO-EXPRESSING ADVANCED OR METASTATIC GASTRIC CANCER WITHOUT PRIOR EXPOSURE TO SYSTEMIC THERAPY

  • Condition/Disease

    HER1/ HER2 CO-EXPRESSING ADVANCED OR METASTATIC GASTRIC CANCER

  • Test Drug

    Varlitinib

Participate Sites
4Sites

Terminated2Sites

Study ended1Sites

2018-07-01 - 2020-06-30

Phase III

A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

  • Condition/Disease

    Pancreatic Cancer

  • Test Drug

    EndoTAG-1

Participate Sites
12Sites

Terminated11Sites

白禮源
China Medical University Hospital-Taipei

未分科

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-06-01 - 2022-06-01

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

1 128 129 130 131 132 172
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB